文献速递冠心病血脂与心血管预防

APOC3与LDL-C降低变异对冠心病风险的联合关联

Joint Associations of APOC3 and LDL-C-Lowering Variants With the Risk of Coronary Heart Disease.
PubMed 文献 · JAMA Cardiol · 2025-01-01

APOC3与LDL-C降低变异联合暴露与冠心病风险进一步降低呈相加关联。

要点

  • 遗传预测较低APOC3与冠心病风险降低相关(OR 0.96)。
  • APOC3与PCSK9降低每10 mg/dL ApoB的冠心病风险降低程度相似。
  • APOC3与LDL-C降低变异联合暴露与冠心病风险相加降低相关。

核心结论

  • 遗传预测较低APOC3与冠心病风险降低相关,其每单位ApoB降低的冠心病风险降低程度与较低PCSK9相似。
  • APOC3与LDL-C降低变异联合暴露与冠心病风险相加降低相关。

主要发现

  • 遗传预测较低APOC3与冠心病风险降低相关(OR 0.96;95%CI 0.93-0.98)及2型糖尿病风险降低相关(OR 0.97;95%CI 0.95-0.99)。
  • 每10 mg/dL ApoB降低,遗传较低APOC3与PCSK9对冠心病风险降低程度相似(APOC3:OR 0.70;95%CI 0.59-0.83;PCSK9:OR 0.71;95%CI 0.65-0.77)。
  • 遗传较低APOC3与PCSK9联合暴露与冠心病风险相加降低相关(APOC3:OR 0.96;95%CI 0.92-0.99;PCSK9:OR 0.93;95%CI 0.90-0.97;联合:OR 0.90;95%CI 0.86-0.93)。
  • 遗传较低HMGCR与冠心病风险降低相关,与APOC3联合时风险进一步降低(OR 0.93;95%CI 0.90-0.97)。

临床怎么用

  • 对于现有降脂治疗未达标的高危患者,APOC3与LDL-C降低联合治疗可能具有进一步降低冠心病风险的潜力。

局限性

  • 研究仅纳入欧洲裔参与者,结果外推需谨慎。
  • 遗传关联研究结果需未来临床试验验证APOC3联合治疗的治疗潜力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Despite substantial progress in low-density lipoprotein cholesterol (LDL-C)-lowering strategies, residual cardiovascular risk remains. Apolipoprotein C3 (APOC3) has emerged as a novel target for lowering triglycerides. Multiple clinical trials of small-interfering RNA therapeutics targeting APOC3 are currently underway. OBJECTIVE: To investigate whether genetically predicted lower APOC3 is associated with a reduction in cardiovascular risk and if the combined exposure to APOC3 and LDL-C-lowering variants is associated with a reduction in the risk of coronary heart disease (CHD). DESIGN, SETTING, AND PARTICIPANTS: This was a population-based genetic association study with 2 × 2 factorial mendelian randomization. Included were participants of European ancestry in the UK Biobank. Data were analyzed from November 2023 to July 2024. EXPOSURES: Genetic scores were constructed to mimic the effects of APOC3, 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), and proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors. MAIN OUTCOMES AND MEASURES: Plasma lipid and lipoprotein levels, CHD, and type 2 diabetes (T2D). RESULTS: This study included 401 548 UK Biobank participants (mean [SD] age, 56.9 [8.0] years; 216 901 female [54.0%]). Genetically predicted lower APOC3 was associated with a lower risk of CHD (odds ratio [OR], 0.96; 95% CI, 0.93-0.98) and T2D (0.97; 95% CI, 0.95-0.99). Genetically lower APOC3 and PCSK9 were associated with a similar magnitude of risk reduction in CHD per 10-mg/dL decrease in apolipoprotein B (ApoB) level (APOC3: 0.70; 95% CI, 0.59-0.83; PCSK9: 0.71; 95% CI, 0.65-0.77). Combined exposure to genetically lower APOC3 and PCSK9 was associated with an additive lower risk of CHD (APOC3: 0.96; 95% CI, 0.92-0.99; PCSK9: 0.93; 95% CI, 0.90-0.97; combined: 0.90; 95% CI, 0.86-0.93). Genetically lower HMGCR was also associated with a lower risk of CHD, and the risk was further reduced when combined with APOC3 (0.93; 95% CI, 0.90-0.97). CONCLUSIONS AND RELEVANCE: Genetically predicted lower APOC3 was associated with a reduced risk of CHD that is comparable with that associated with lower PCSK9 per unit decrease in ApoB. Combined exposure to APOC3 and LDL-C-lowering variants was associated with an additive reduction in CHD risk. Future studies are warranted to investigate the therapeutic potential of these combined therapies, particularly among high-risk patients who cannot achieve therapeutic targets with existing lipid-lowering therapies.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Wang W, Li R, Song Z, et al. Joint Associations of APOC3 and LDL-C-Lowering Variants With the Risk of Coronary Heart Disease. JAMA Cardiol. 2025. PMID: 40105833. doi:10.1001/jamacardio.2025.0195

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。